P/E ratio for Genscript Biotech (1548.HK)
P/E ratio at the end of 2021: -23.1
According to Genscript Biotech 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -7.75325. At the end of 2021 the company had a P/E ratio of -23.1.
P/E ratio history for Genscript Biotech from 2015 to 2021
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2021 | -23.1 | 73.76% |
| 2020 | -13.3 | -69.78% |
| 2019 | -43.9 | -140.01% |
| 2018 | 110 | -34.63% |
| 2017 | 168 | 457.76% |
| 2016 | 30.1 | 162.45% |
| 2015 | 11.5 |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.